{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-092691","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2026-08-07T20:06:19+00:00","discovered_at":"2026-08-07T20:08:00.347361+00:00","generated_at":"2026-08-07T20:08:34.236364+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"CytoSorbents Q2 2026 presentation omits financials; targets H2 2026 break-even","bullets":["Targets operating cash-flow break-even in H2 2026 via strategic workforce and cost reduction plan.","Restructuring direct sales team and strategy in Germany; cites war in Iran as a risk factor.","Seeks FDA and Health Canada regulatory approval; must comply with existing debt covenants.","Q2 2026 earnings presentation dated Aug 6, 2026; no specific revenue or EPS figures in furnished exhibit."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-092691","json":"https://secwatch.observer/filing/0001104659-26-092691.json","markdown":"https://secwatch.observer/filing/0001104659-26-092691.md","text":"https://secwatch.observer/filing/0001104659-26-092691.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926092691/0001104659-26-092691-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926092691/tm2622604d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-07T20:08:34.236364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}